Amicus Therapeutics (FOLD) Accounts Payables (2016 - 2025)
Amicus Therapeutics (FOLD) has disclosed Accounts Payables for 16 consecutive years, with $28.6 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Accounts Payables rose 121.13% year-over-year to $28.6 million, compared with a TTM value of $28.6 million through Dec 2025, up 121.13%, and an annual FY2025 reading of $28.6 million, up 121.13% over the prior year.
- Accounts Payables was $28.6 million for Q4 2025 at Amicus Therapeutics, up from $19.1 million in the prior quarter.
- Across five years, Accounts Payables topped out at $32.1 million in Q2 2024 and bottomed at $9.2 million in Q1 2024.
- Average Accounts Payables over 5 years is $18.5 million, with a median of $15.8 million recorded in 2021.
- Peak annual rise in Accounts Payables hit 137.07% in 2024, while the deepest fall reached 63.11% in 2024.
- Year by year, Accounts Payables stood at $21.5 million in 2021, then decreased by 28.35% to $15.4 million in 2022, then fell by 1.9% to $15.1 million in 2023, then decreased by 14.37% to $12.9 million in 2024, then soared by 121.13% to $28.6 million in 2025.
- Business Quant data shows Accounts Payables for FOLD at $28.6 million in Q4 2025, $19.1 million in Q3 2025, and $13.9 million in Q2 2025.